MedTrace Logo

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

NCT01678105 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2015-09-17

No results posted yet for this study

Summary

This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to assess the anti-cancer effects of dovitinib in this population in order to evaluate whether dovitinib is worthy of further study in patients with progressive ACC.

Conditions

  • Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
  • Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
  • Salivary Gland Cancers
  • ACC

Interventions

DRUG

Dovitinib

Treatment continued until Disease Progression, Toxicity, or patient withdrawal

Sponsors & Collaborators

Principal Investigators

  • Sebastien Hotte, MD · Juravinski Cancer Centre

  • Mark Levine, MD · Ontario Clinical Oncology Group (OCOG)

  • Greg Pond, PhD · Ontario Clinical Oncology Group (OCOG)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678105 on ClinicalTrials.gov